Farragher, Tracey M <br/><br/>
Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies.  [electronic resource] 

 -  Arthritis care & research  May 2010 
 - 664-75 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2151-4658 
<br/><br/><label>Standard No.: </label>10.1002/acr.20207  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antirheumatic Agents--therapeutic use<br/>Arthritis--blood<br/>Arthritis, Rheumatoid--blood<br/>Autoantibodies--blood<br/>Cohort Studies<br/>Disease Progression<br/>Female<br/>Humans<br/>Longitudinal Studies<br/>Male<br/>Middle Aged<br/>Peptides, Cyclic--immunology<br/>Predictive Value of Tests<br/>Registries<br/>Rheumatoid Factor--blood<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Young Adult